2023년에 4억 4,020만 달러로 추정되는 경피 스코폴라민 세계 시장은 2023-2030년간 CAGR 5.3%로 성장하여 2030년에는 6억 3,050만 달러에 이를 것으로 예측됩니다.
미국 시장은 1억 3,330만 달러, 중국은 CAGR 5%로 성장 예측
미국 경피 스코폴라민 시장은 2023년에 1억 3,330만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023년부터 2030년까지 분석 기간에 CAGR 5%로 성장을 지속하여, 2030년까지 1억 1,070만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서 일본과 캐나다가 있으며, 각각 2023-2030년간5%로 4.2%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 4.4%로 성장할 것으로 예측됩니다.
2024년 매력적인 새로운 보고서 기능 소개
인플루언서 참여 통계에 풀 액세스
디지털 아카이브와 'MarketGlass' 리서치 플랫폼에 무료로 액세스하세요. 당사의 독자적인 MarketGlass 플랫폼은 전 세계 전문가들의 창의성과 시장 지식을 통합적이고 협력적으로 발휘할 수 있도록 지원합니다. 당사의 최첨단 툴은 시장 진출기업의 프라이버시와 신원을 보호하면서 세계적 수준의 시장 관점을 제공합니다. 이 보고서의 수치, 통계 및 시장 설명은 해당 분야의 전문가와 인플루언서들이 공유한 엄선된 인사이트를 기반으로 합니다.
실시간 데이터 시뮬레이터 툴이나 맞춤형 보고서 작성 기능을 갖춘 인터랙티브인 설문조사에 참가할 수 있습니다.
기업 간의 스마트한 의견 교환을 위한 동료 협업 및 대화형 플랫폼에 대한 전체 클라이언트 액세스 권한 부여
1년간 무료 보고서 업데이트
주요 기업 - 세계 시장 점유율을 포함한 경쟁 커버리지
여러 지역에서 기업의 시장 포지셔닝 분석(호조/활발/니치/마이너)
전문가/기업 인터뷰, 팟캐스트, 프레스 발표, 이벤트 기조 강연 YouTube 비디오 액세스
2024년 세계 경제에 기대하는 것
금융긴축과 그에 따른 금리 상승에 의해 발생하는 지정학적/경제적 불안정성이 2024년 격동 상황을 만들어 낼 것으로 예상됩니다. 중동의 적대 행위와 점점 더 빈번해지는 기후 재난 등여러 요인이 복구의 길에 계속 압력을 가할 것입니다. 이러한 리스크 가운데 디스인플레이션의 조짐과 고질적인 인플레이션에 대한 불안감 완화, 공급망 정상화, 에너지 비용의 변동성에도 불구하고 가격 조정 등 몇 가지 긍정적인 요소도 구체화되고 있습니다. 인도나 미국을 비롯한 G21 국가 선거는 자본 흐름이나 투자 전략에 영향을 미치는 가능성이 있습니다. 인도가 글로벌 투자 환경에서 매력적인 투자처로 부상하고 있지만, 미국에 기반을 둔 기술 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속해서 우위를 점할 것입니다. 실리콘밸리를 시작으로 하는 하이테크 기업 투자 기회는 국내 경제가 감속하고 있다고는 해도 안정적이고, 규제 환경도 정비되고 있는 것부터, 고성장 가능성을 요구하는 투자자에 있어서 계속 매력적입니다. 유럽은 금융긴축정책과 경기후퇴 리스크와의 싸움이 계속 되지만, 영국은 전망이 가장 어렵고, 2024년 경기후퇴 리스크가 가장 높습니다. 중국은 정부 지출과 소비자 지출의 개선에 힘입어 성장에 대한 희망을 품고 있는 와일드카드로 남아 있습니다. 변동성이 큰 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 제공할 것입니다. 투자 결정을 내릴 때 민첩성과 전략적 선견지명과 함께 변동성을 성장의 촉매제로 받아들이는 것이 생존을 위해 여전히 중요할 것입니다.
조사 대상 기업 예(총 41개사)
Alchem International
Alkaloids of Australia
ALZA Corporation
Baxter International Inc.
Caleb Pharmaceuticals Inc
Centroflora-Cms
Fine Chemicals Corporation
GlaxoSmithKline Plc
Myungmoon Pharma Co. Ltd.
Novartis AG
Perrigo Co. Plc
Phytex Australia
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
세계 기타 지역
제4장 경쟁
LSH
영문 목차
영문목차
Global Transdermal Scopolamine Market to Reach $630.5 Million by 2030
The global market for Transdermal Scopolamine estimated at US$440.2 Million in the year 2023, is expected to reach US$630.5 Million by 2030, growing at a CAGR of 5.3% over the period 2023-2030.
The U.S. Market is Estimated at $133.3 Million, While China is Forecast to Grow at 5% CAGR
The Transdermal Scopolamine market in the U.S. is estimated at US$133.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$110.7 Million by the year 2030 trailing a CAGR of 5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Select Competitors (Total 41 Featured) -
Alchem International
Alkaloids of Australia
ALZA Corporation
Baxter International Inc.
Caleb Pharmaceuticals Inc
Centroflora-Cms
Fine Chemicals Corporation
GlaxoSmithKline Plc
Myungmoon Pharma Co. Ltd.
Novartis AG
Perrigo Co. Plc
Phytex Australia
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Transdermal Scopolamine - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Transdermal Scopolamine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 5: USA Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 6: USA Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CANADA
TABLE 7: Canada Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 8: Canada Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
JAPAN
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 9: Japan Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 10: Japan Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CHINA
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 11: China Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 12: China Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
EUROPE
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 13: Europe Recent Past, Current & Future Analysis for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 14: Europe Historic Review for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 15: Europe 16-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 16: France Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 17: France Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
GERMANY
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 18: Germany Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 19: Germany Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ITALY
TABLE 20: Italy Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: Italy Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
UNITED KINGDOM
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 22: UK Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 23: UK Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF EUROPE
TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 25: Rest of Europe Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ASIA-PACIFIC
Transdermal Scopolamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: Asia-Pacific Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF WORLD
TABLE 28: Rest of World Recent Past, Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 29: Rest of World Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
